Unichem Laboratories. Photo: UnichemLabs.com
Unichem Laboratories Ltd on Thursday said it has received approval from the US health regulator to market its generic version of tolterodine tartrate tablets used in the treatment of overactive urinary bladder.
The approval by the US Food and Drug Administration (USFDA) to market tolterodine tartrate tablets is for strengths of 1 mg and 2 mg, Unichem Laboratories said in a regulatory filing.
The tolterodine tartrate tablets are generic versions of Pfizer Inc's DETROL tablets, it added.
The tablets are indicated for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
The product will be commercialised from Unichem's Goa plant, the company said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Aug 06 2020 | 5:13 PM IST